Core Viewpoint - CITIC Securities maintains a target price of HKD 177 for CanSino Biologics (09926) and a "outperform" rating following the positive trends observed in the global Phase III Harmoni study data for ivonescimab in treating second-line EGFR+ non-small cell lung cancer (NSCLC) [1] Group 1 - The Harmoni study data shows an improvement in overall survival (OS) risk trend from 0.79 to 0.78 [1] - The risk ratios reported for North America and Asia subgroups are 0.7 and 0.76, respectively, indicating strong performance [1] - The next key catalyst to watch is the results from the Phase III head-to-head clinical trial of Harmoni-6 versus tislelizumab, which will be presented at the 2025 European Society for Medical Oncology (ESMO) [1]